Lou B, et al. - Researchers analyzed data from articles, identified via a systematic search of PubMed, EMBASE and Web of Science databases, comparing the clinical efficacy and safety of dual vs single antiplatelet therapy in combination with antithrombotic therapy in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI). Articles published up to October 31th, 2017 were selected. Dual antiplatelet therapy together with warfarin or new oral anticoagulation (NOAC) (triple antithrombotic therapy, TT) was received by 5066 participants and single antiplatelet therapy together with warfarin or NOAC (dual antithrombotic therapy, DT) by 5795 participants. In this meta-analysis of eight studies involving a total of 10861 patients with AF, DT vs TT showed equal efficacy in attenuating stroke, in-stent thrombosis, Major Adverse Cardiovascular Events (MACE) and all-cause mortality rate, but demonstrated beneficial impact in reducing overall bleeding incidence.